US 11673893
CDK inhibitors and their use as pharmaceuticals
granted A61KA61K31/4545A61K31/506
Quick answer
US patent 11673893 (CDK inhibitors and their use as pharmaceuticals) held by Prelude Therapeutics, Incorporated expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Prelude Therapeutics, Incorporated
- Grant date
- Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61K, A61K31/4545, A61K31/506, A61P, A61P35/00